Scoop: Linden pays around 15x EBITDA for Relevate Health

Linden Capital paid 15x to 16x EBITDA for pharma marketing business Relevate Health from Mountaingate Capital, Axios Pro has learned.

• The business was marketed on about $35 million of EBITDA, four sources say.

The big picture: Mountaingate announced its exit on Monday, but did not disclose the buyer or price.